About SBI

Diseases of the brain and central nervous system have the single largest impact on society, larger than any other disease area. In Europe alone, the estimated impact on society of these diseases is estimated to be well over 800 billion € and these diseases affect about one third of the population. Today, following numerous failures in clinical trials, many large pharmaceutical companies have decided to largely abandon research and development in CNS diseases, including all companies in Sweden. No fundamental treatments exist or are in sight for most disorders of the CNS, leaving a large unmet and unaddressed need. This development is unfortunate and will thus be in conflict with the increase in life expectancy and the future increases in prevalence of CNS-related diseases. Finally, it is clear that progress in the basic neurosciences is not effectively being translated into medical innovations.

The Berzelii Centre Stockholm Brain Institute (Centre) offers an academic-innovation space for public and private partners to collaborate in scientific projects. This Centre serves as a base for internationally leading and developing research groups from three Stockholm area universities, Karolinska Institutet (KI), Royal Institute of Technology (KTH) and Stockholm University (SU). Through collaboration with industrial partners from the biomedical, biotechnical and pharmaceutical industry, and with public partners in health care and education, we seek to exploit the development and commercialisation of our research findings. These efforts will

1) identify and develop biomarkers and other translational neuroscience efforts to detect and follow disease progression,

2) develop new technologies that will support new and better treatments and

3) initiate novel treatments, including drug discovery and development programs either organically or in collaboration with our partners’ on-going programs.

The Stockholm Brain Institute can be regarded as a platform for collaboration between academy and industry where the aim is to facilitate the process of taking results to the market. By having a close collaboration with StratNeuro, which is a network of researchers involved in basic neuroscience research, SBI can early identify interesting projects that can be brought in into SBI. SBI Director being innovation officer for StratNeuro further facilitates this and SBI project coordinator is also project coordinator for StratNeuro.

The platforms are important for support to ongoing project at SBI and SBI encourage cross platform collaboration if possible in order to increase project success rate. Presentations at retreats of platforms are important in order for SBI partner to become familiar of what resources are available for collaboration.

An important function for SBI is to identify promising results that can lead to new inventions. Young researchers need to be aware of the importance of innovation, what it means for society, and how industry operates. Therefore important elements in the SBI school training are knowledge about innovation systems and contacts with private industry.

Vision

The Berzelii Centre Stockholm Brain Institute (Centre) will work collaboratively to identify and exploit innovations from our translational neuroscience research to specifically address the enormous unmet need in brain disorders and to markedly improve patient’s lives and the burden on society.

Mission

Our mission is to be an internationally recognised centre in translational neurosciences that attracts, develops and commercialises partnerships with the private and public sectors. Through these partnerships we will develop joint projects that exploit our expertise to lead to novel ways to diagnose, treat, or prevent brain disorders.

The SBI objectives are:

  • Innovative research in collaboration with the public and private sectors that meets specific needs of society by

1) identifying and developing biomarkers and other translational neuroscience efforts to detect and follow disease progression,

2) developing new technologies that will support new and better treatments and

3) initiate novel treatments, including drug discovery and development programs either organically or in collaboration with our partners’ on-going programs.

  • International leadership in translational neuroscience
  • Sustainability

 

Share Button